Study Supports ADC as a New Option for Endocrine-Resistant Metastatic Breast Cancer Datopotamab deruxtecan was safe and boosted quality of life Dec 08, 2023
Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC But better safety profile versus continued pembrolizumab plus chemotherapy Dec 08, 2023
Study 'Underscores' Value of Early Fertility Counseling for Breast Cancer Patients Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy Dec 08, 2023
Adding Immunotherapy to Neoadjuvant Chemo Boosts pCR in HR-Positive Breast Cancer Promising early results with pembrolizumab, nivolumab but event-free survival data still pending Dec 07, 2023
No Benefit to Adjuvant-Only Immunotherapy in Early TNBC Neoadjuvant administration of immunotherapy remains the preferred approach Dec 07, 2023
De-Escalating Breast Cancer Treatment Feasible After Response to Neoadjuvant Chemo Study showed no increase in disease progression when omitting regional nodal irradiation Dec 07, 2023
Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer Adding agent to T-DM1 resulted in 2-month progression-free survival improvement Dec 06, 2023
High Rates of pCR With Novel Neoadjuvant Combination for Breast Cancer Enthusiasm tempered by immune-related adverse events, diabetes with PD-1/LAG-3 combination Dec 11, 2022
Less Is More Wins Again: Avoiding Node Dissection in Early Breast Cancer First comparison of targeted sentinel node assessment shows no difference in recurrence rates Dec 09, 2022
Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer In phase III trial, capivasertib benefited patients with or without AKT pathway alterations Dec 09, 2022
Oral SERD Tops Fulvestrant for PFS in ER-Positive Breast Cancer Camizestrant also led to meaningful PFS improvements in those with detectable ESR1 mutations Dec 09, 2022
Continuing CDK4/6 Inhibitor Beyond Progression No Help in Metastatic Breast Cancer Prior therapy, baseline mutations confound results; "intriguing" benefit with PD-L1 inhibitor Dec 09, 2022
Pausing Endocrine Therapy for Pregnancy Safe in Early Breast Cancer Study suggests no increased risk of cancer recurrence versus historical control Dec 09, 2022
T-DXd Continues Winning Streak in Metastatic, HER2-Positive Breast Cancer Trastuzumab deruxtecan improves survival in second- and later-line settings Dec 08, 2022
Neoadjuvant T-DXd Active in HER2-Low Breast Cancer Response rates on the order of 58-68%, with or without endocrine therapy Dec 08, 2022
Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancer No improvement in the overall analysis but a hint of benefit in premenopausal patients Dec 08, 2022
Assay Predicts Breast Cancer Patients Who Will Benefit From Ovarian Suppression Low score suggests improved outcomes with ovarian suppression plus adjuvant endocrine therapy Dec 07, 2022
First-Line CDK4/6 Thumps Chemo in Aggressive, Advanced Breast Cancer Doubling of PFS could be death knell for combination chemotherapy in difficult-to-treat subgroup Dec 07, 2022
Metastasis 'Doorway' May Lead to Racial Disparities in Breast Cancer Density of cellular complex after neoadjuvant therapy tied to cancer subtypes, may be targetable Dec 07, 2022
Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancer No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancer Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancer Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancer Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancer Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancer Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
Highly Mutated Breast Cancer Responds to Immunotherapy Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Site Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Status However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancer Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
Black Women Most at Risk for Post-Surgical Lymphedema Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancer Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
Genomic Profiling Improves Outcomes in Breast Cancer PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancer Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
Add-On HDAC Inhibitor No Help in Breast Cancer PFS, OS similar to endocrine therapy alone for advanced HR+ disease Dec 15, 2020
Online Tool Refines Individual Risks in Breast Cancer RSClin incorporates 21-gene recurrence score with tumor grade, size, and more Dec 13, 2020
Doctor-Patient Discord in Reporting Radiation Toxicity Physicians underrecognized substantial symptoms in more than half of patients Dec 11, 2020
Adjuvant Palbociclib Fails in Early, High-Risk Breast Cancer No iDFS benefit with 1 year of CDK4/6 inhibition following neoadjuvant chemotherapy Dec 10, 2020
Oral Paclitaxel Bests IV Delivery in Advanced Breast Cancer But high pill count, lengthy dosing schedule could prove to be problematic Dec 14, 2019
Residual Breast Cancer Tool Highly Prognostic After Neoadjuvant Tx Tumor burden calculator predicted long-term outcomes in all breast cancer subtypes Dec 14, 2019
Anti-CDK4/6 Fails to Top Chemo in HR-Positive MBC Similar PFS with chemo, palbociclib plus exemestane or fulvestrant after progression on aromatase inhibitor Dec 13, 2019
